CompletedPhase 4

Research of Exenatide for Overweight/Obese PCOS Patients With IGR

China183 participantsStarted 2017-11-28

Plain-language summary

Compare the therapeutic effects of exenatide, metformin and their combination for 3 months on reproductive and metabolic improvements of overweight/obese PCOS patients with impaired glucose regulation.

Who can participate

Age range18 Years – 45 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. have PCOS which is diagnosed according to 2003 Rotterdam criteria;
✓. overweight / obesity diagnostic criteria is based on WHO-WPR ;
✓. IGR diagnostic criteria is based on 1999 WHO diagnostic criteria;
✓. have been treated with dietary and behavioral intervention for 3 months but are ineffective;
✓. have no use of other hypoglycemic drugs before 3 months of treatment.

What they're measuring

Improvement of intravenous blood glucose from impaired glucose regulation to normal glucose regulation

Timeframe: up to 12 weeks

Trial details

NCT IDNCT03352869

SponsorRenJi Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2018-07-01

View on ClinicalTrials.gov More Polycystic Ovary Syndrome trials